Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Intellia Therapeutics, Inc.NASDAQ: NTLA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow grows to $33.57M
Q1 FY2026 financing cash flow was $33.57M, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $165.06M. Over 3 fiscal years it compounded at -31.7% a year.
Context
- Financing cash flow amounted to 274.5% of revenue in FY2025, down 46.4 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near $33.57M or moves back toward the trailing-twelve-month quarterly average of $41.26M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 185.75M USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- -29.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 185.75M | +0.0% |
| FY2024 | 2024-12-31 | 185.75M | +42.5% |
| FY2023 | 2023-12-31 | 130.32M | -77.6% |
| FY2022 | 2022-12-31 | 582.96M | -20.9% |
| FY2021 | 2021-12-31 | 736.69M | — |
Financing Cash Flow vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's LTM Mar 2026 financing cash flow of $165.06M is the 3rd largest of the 10 companies compared; the peer median is $92.57M.
- Its year-over-year change of +31.3% is the 5th highest of 10, against a peer median of -14.4%.
- Financing cash flow amounts to 249.7% of revenue for NTLA, versus a peer median of 108.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $719.96M | +120.5% | +122.7% | 2860.1% | |
| LTM Mar 2026 | $329.26M | +1454.3% | +560.0% | 1819.8% | |
| LTM Mar 2026 | $165.06M | +31.3% | -31.7% | 249.7% | |
| LTM Mar 2026 | $127.62M | +790.4% | +197.0% | — | |
| LTM Jun 2026 | $107.69M | -77.5% | +62.4% | 69.0% | |
| LTM Jun 2026 | $92.57M | -14.4% | — | 108.0% | |
| LTM Mar 2026 | $41.91M | -23.0% | +215.9% | 108.3% | |
| LTM Mar 2026 | $7.05M | +49.8% | +31.2% | 62.9% | |
| LTM Mar 2026 | $446K | -99.2% | -49.5% | 0.6% | |
| LTM Mar 2026 | $155K | -99.9% | -90.2% | — | |
| Peer median (excluding NTLA) | $92.57M | -14.4% | +92.5% | 108.0% | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (519.02M) |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 10.29M |
| Deferred Income Tax | 8.93M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 47.01M | 91.4M | 134.05M | 154.27M | 154.27M |
| Change in Working Capital | (22.9M) | (53.87M) | (52.45M) | 11.88M | (73.75M) |
| Accounts Receivables | 99K | (1.74M) | (32.69M) | 27.94M | (951K) |
| Inventory | 7.82M | 0 | 0 | 0 | 0 |
| Accounts Payables | 529K | (4.58M) | 2.52M | 6.8M | 5.99M |
| Other Working Capital | (31.36M) | (47.55M) | (22.29M) | (22.86M) | (78.79M) |
| Other Non-Cash Items | 2.94M | 95.8M | (3.47M) | (6.3M) | 79.34M |
| Operating Cash Flow | (225.03M) | (333.29M) | (394.09M) | (348.88M) | (348.88M) |
| Capital Expenditures | (12.76M) | (58.39M) | (13.99M) | (5.78M) | (5.78M) |
| Acquisitions (Net) | (3M) | (44.68M) | 0 | 0 | 0 |
| Purchases of Investments | (1.02B) | (429.03M) | (904.46M) | (935.57M) | (935.57M) |
| Sales of Investments | 485.6M | 647.58M | 887.1M | 1.07B | 1.05B |
| Other Investing Activities | 0 | 44.83M | 0 | 0 | 20.97M |
| Investing Cash Flow | (550.78M) | 160.31M | (31.35M) | 125.57M | 125.57M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 693.57M | 565.79M | 119.8M | 176.9M | 131.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 43.12M | 17.17M | 10.53M | 8.85M | 54.26M |
| Financing Cash Flow | 736.69M | 582.96M | 130.32M | 185.75M | 185.75M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (39.12M) | 409.98M | (295.11M) | (37.57M) | (37.57M) |
| Free Cash Flow | (237.79M) | (391.68M) | (408.07M) | (354.66M) | (354.66M) |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.